Hbv Hcv published presentations and documents on DocSlides.
-. Ritonavir . and Dasabuvir . + RBV in . GT1. SA...
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
+ . Grazoprevir. in . GT 1 . and Chronic Renal ...
HEPATITIS. Hepatitis. -Is inflammation of the liv...
. + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase...
Bloodborne. . Pathogen Training. Biological Safe...
AIDS 2016 | 18-22 July 2016 | Durban, South A...
qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years....
Harvoni. ). Prepared by: . David H. Spach, MD and...
With Or Without Ribavirin Is Safe and Efficacious...
Hepatitis-2015. Orlando, USA. July 20 - 22 2015...
with PEG + RBV in Genotype 1. SPRINT. -1. Phase ....
SPRINT-2. Phase 3, Treatment . Naive. Treatment. ...
John Scott, MD, MSc. Associate Professor, Univers...
VALENCE Trial. Phase . 3. Treatment. Naïve and ...
Bloodborne Pathogen Final Rule. Module . B. Almos...
Open label. ≥ . 18 years, . HCV genotype 1 to ...
Number People with Reactive anti-HCV Antibody. Un...
immune escape . mutants. Anders Boyd, MPH, . PhD....
OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open labe...
Hilda T Marima- Matarira. Professor of Chemical P...
Design. LDV/SOF. Open-label. ION-4 . Study. : LDV...
qd. Non-randomised. Open-label. N =. 21. W12. SV...
Open-label. Chronic HCV infection. Genotype 1 . F...
W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...
David Spach, MD. Clinical Director, Northwest AET...
Randomisation*. Open-label. >. 18 years. HCV ...
Nina Kim, MD . Associate Professor of Medicine. D...
Hepatitis-2015. Orlando, USA. July 20 - 22 2015...
Open label. ≥ . 18 years, . HCV genotype 1 to ...
. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...
C. IN PEOPLE WHO USE DRUGS. Improving . Care for ...
Associate Professor, Johns Hopkins Bloomberg Scho...
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
LANDLORD BRIEFING. 2015. KHRA & HCV ~ Overvie...
Updated: . July . 6. , . 2015. Treatment of Hepat...
BID versus q8 in Treatment Naïve GT-1. OPTIMIZE ...
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
in DAA. -Naïve GT . 1-6 . POLARIS-2. Phase 3. ...
Copyright © 2024 DocSlides. All Rights Reserved